

Evidence-Based Clinical Pathway: Supratherapeutic INR due to Warfarin

Prepared by: Cory B, Schieche C, Gentges J

06/30/14 replaces no older version

Primary Sources: Holbrook A, Schulman S, Witt D. Evidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2_suppl):e152S-e184S. doi:10.1378/chest.11-2295. Ansell J, Hirsh J, Hylek E. Pharmacology and Management of the Vitamin K Antagonists*: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133(6_suppl):160S-198S. doi:10.1378/chest.08-0670 Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. *Transfusion*. 2009 Jun;49(6):1171-Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. *J Am Coll Cardiol* 2006; 47:804.Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. *Ann Intern Med* 2009; 150:293.

Pathway applicability:
Patients with supratherapeutic INR due to warfarin

Medication Dosage Guide

Dosage for 4 Factor PCC:
Pretreatment INR 2 to <4: Give **25 units/kg IV** (max 2500 units)
Pretreatment INR 4 to 6: Give **35 units/kg IV** (max 3500 units)
Pretreatment INR above 6: Give **50 units/kg IV** (max 5000 units)

Dosage for FFP: **15-30 mL/kg IV** (Usually 2-4 units)

Dosage for Recombinant factor VII: **90mcg/kg IV**

Dosage for 3 Factor PCC: **50 units/kg IV**

Pathway applicability:

Patients with supratherapeutic INR due to warfarin

Evidence of serious or life threatening bleeding?

No

Yes

What is the INR?

4.5-10

>10.0

1: Omit 1 or 2 doses of warfarin
2: Recheck INR in 1-3 days
3: Resume warfarin when INR in therapeutic range

1: Hold warfarin
2: **Vit. K 2.5-5.0 mg PO**
3: Recheck INR in 1-3 days
4: Resume warfarin when INR in therapeutic range

1: Hold warfarin
2: **Vit. K 10mg IV q12h**
3: Give **4 Factor PCC** (preferred) per dosage guide OR give **3 Factor PCC**
4: Verify INR normalization in 30 min

Consider discharge for patients with close followup and the ability to follow discharge instructions (avoid falls, accidents, strenuous activity)

Consider admission for observation (fall risk, poor follow up, history of anticoagulation related bleeding, active bleeding)

1: Give **FFP 15-30 mL/kg IV**
2: Recheck INR in 1-2 hours

No

INR normalized (<1.5)?

Yes

Proceed with definitive therapy for life threatening bleeding